Valuation: Everest Organics Limited

Market Cap 2.48B 26.41M 23.58M 21.69M 19.69M 37.31M 38.24M 260M 103M 1.33B 99.14M 97.02M 4.17B P/E 2025
-190x
P/E 2026 35.7x
Enterprise Value 2.97B 31.67M 28.27M 26.01M 23.61M 44.74M 45.85M 311M 124M 1.59B 119M 116M 5.01B EV / Sales 2025
1.79x
EV / Sales 2026 1.25x
Free-Float
22.73%
Yield 2025 *
-
Yield 2026 -
1 day+1.47%
1 week+8.77%
Current month+8.77%
1 month+5.35%
3 months-14.85%
6 months-2.60%
Current year-49.59%
1 week 229
Extreme 229
255.45
1 month 214.05
Extreme 214.05
262
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 110
Extreme 110
536.4
5 years 95
Extreme 95
536.4
10 years 44.45
Extreme 44.45
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 28/09/2015
Director TitleAgeSince
Director/Board Member 71 13/11/2024
Director/Board Member - 14/08/2026
Director/Board Member 47 29/09/2007
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%+8.77%-37.76%+113.35% 25.95M
+4.40%+0.16%+46.21%+139.00% 1,206B
+1.98%+4.15%+49.56%+91.15% 665B
+0.66%+1.57%+34.14%+112.53% 515B
+2.77%+0.98%+43.81%+68.46% 381B
+1.07%+0.07%+71.14%+45.01% 362B
+0.29%+1.48%+30.59%+58.32% 307B
+0.98%+1.49%+7.16%+34.78% 289B
+0.79%-0.36%+43.29%+75.63% 249B
+1.51%-0.60%+43.30%+125.81% 207B
Average +1.48%-1.19%+33.14%+86.40% 417.98B
Weighted average by Cap. +2.14%-1.96%+43.03%+96.02%

Financials

2025 2026
Net sales 1.6B 17.06M 15.23M 14.02M 12.72M 24.11M 24.71M 168M 66.83M 856M 64.05M 62.68M 2.7B 1.97B 20.99M 18.73M 17.24M 15.64M 29.65M 30.38M 206M 82.18M 1.05B 78.77M 77.08M 3.32B
Net income -12.9M -138K -123K -113K -103K -194K -199K -1.35M -539K -6.91M -517K -506K -21.76M 55.46M 592K 528K 486K 441K 836K 857K 5.81M 2.32M 29.69M 2.22M 2.17M 93.52M
Net Debt 412M 4.4M 3.93M 3.61M 3.28M 6.21M 6.37M 43.22M 17.23M 221M 16.51M 16.16M 695M 493M 5.26M 4.69M 4.32M 3.92M 7.43M 7.61M 51.66M 20.59M 264M 19.74M 19.31M 831M
Projected Income Statement - Annual - Everest Organics Limited
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
316
Date Price Change Volume
09/11/26 ₹254.95 +1.47% 420
08/11/26 ₹251.25 +5.13% 23
06/11/26 ₹239.00 -0.85% 16
05/11/26 ₹241.05 +0.48% 99
04/11/26 ₹239.90 +1.87% 258
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock